user

HIV-1 Proviral Sequence and Treatment Outcome of Virologically Suppressed Patients Switching to Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate (vol 79, pg e45, 2018)

被引：0
|
作者：
Andreatta, K.
Chang, S.
Martin, R.
Acosta, R.
Daeumer, M.
Thielen, A.
Miller, M. D.
White, K. L.
机构：
来源：
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES | 2018年 / 79卷 / 04期
关键词：
D O I：
10.1097/QAI.0000000000001892
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：E111 / E111
页数：1
相关论文
共 50 条
  • [21] Virological failure in two patients with HIV-1 RNA viral loads >1,000,000 copies/ml initiated on elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate
    Adams, Jessica L.
    Byrne, Dana
    Pepe, Rosalie
    Gray, Anastasia
    Baxter, John D.
    [J]. ANTIVIRAL THERAPY, 2016, 21 (02) : 175 - 180
  • [22] A Randomized, Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF vs Ritonavir-Boosted Atazanavir Plus Coformulated Emtricitabine and Tenofovir DF for Initial Treatment of HIV-1 Infection: Analysis of Week 96 Results (vol 62, pg 483, 2013)
    Rockstroh, J.
    DeJesus, E.
    Henry, K.
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2013, 63 (05) : E171 - E171
  • [23] Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial
    Maggiolo, Franco
    Rizzardini, Giuliano
    Raffi, Francois
    Pulido, Federico
    Gracia Mateo-Garcia, Maria
    Molina, Jean-Michel
    Ong, Edmund
    Shao, Yongwu
    Piontkowsky, David
    Das, Moupali
    McNicholl, Ian
    Haubrich, Richard
    [J]. LANCET HIV, 2019, 6 (10): : E655 - E666
  • [24] Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial
    Orkin, Chloe
    Molina, Jean-Michel
    Negredo, Eugenia
    Arribas, Jose R.
    Gathe, Joseph
    Eron, Joseph J.
    Van Landuyt, Erika
    Lathouwers, Erkki
    Hufkens, Veerle
    Petrovic, Romana
    Vanveggel, Simon
    Opsomer, Magda
    [J]. LANCET HIV, 2018, 5 (01): : E23 - E34
  • [25] Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial
    DeJesus, Edwin
    Rockstroh, Juergen K.
    Henry, Keith
    Molina, Jean-Michel
    Gathe, Joseph
    Ramanathan, Srinivasan
    Wei, Xuelian
    Yale, Kitty
    Szwarcberg, Javier
    White, Kirsten
    Cheng, Andrew K.
    Kearney, Brian P.
    [J]. LANCET, 2012, 379 (9835): : 2429 - 2438
  • [26] Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study
    DeJesus, Edwin
    Ramgopal, Moti
    Crofoot, Gordon
    Ruane, Peter
    LaMarca, Anthony
    Mills, Anthony
    Martorell, Claudia T.
    de Wet, Joseph
    Stellbrink, Hans-Jurgen
    Molina, Jean-Michel
    Post, Frank A.
    Valero, Ignacio Perez
    Porter, Danielle
    Liu, Yapei
    Cheng, Andrew
    Quirk, Erin
    SenGupta, Devi
    Cao, Huyen
    [J]. LANCET HIV, 2017, 4 (05): : E205 - E213
  • [27] Impact of Switching From Zidovudine to Tenofovir Disoproxil Fumarate on Bone Mineral Density and Markers of Bone Metabolism in Virologically Suppressed HIV-1 Infected Patients; A Substudy of the PREPARE Study
    Cotter, Aoife G.
    Vrouenraets, Saskia M. E.
    Brady, Jennifer J.
    Wit, Ferdinand W.
    Fux, Christoph A.
    Furrer, Hansjakob
    Brinkman, Kees
    Sabin, Caroline A.
    Reiss, Peter
    Mallon, Patrick W. G.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2013, 98 (04): : 1659 - 1666
  • [28] Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study
    Orkin, Chloe
    DeJesus, Edwin
    Ramgopal, Moti
    Crofoot, Gordon
    Ruane, Peter
    LaMarca, Anthony
    Mills, Anthony
    Vandercam, Bernard
    de Wet, Joseph
    Rockstroh, Jurgen
    Lazzarin, Adriano
    Rijnders, Bart
    Podzamczer, Daniel
    Thalme, Anders
    Stoeckle, Marcel
    Porter, Danielle
    Liu, Hui C.
    Cheng, Andrew
    Quirk, Erin
    SenGupta, Devi
    Cao, Huyen
    [J]. LANCET HIV, 2017, 4 (05): : E195 - E204
  • [29] A phase IV, open-label three-arm study investigating the impact of a combination of tenofovir disoproxil fumarate/emtricitabine with raltegravir or dolutegravir or elvitegravir/cobicistat on renal function in HIV-1 antiretroviral naive patients
    Bracchi, Margherita
    Pagani, Nicole
    Dalla Pria, Alessia
    Milinkovic, Ana
    Nwokolo, Nneka
    Thomas, Lervina
    Mandalia, Sundhyia
    Boffito, Marta
    Moyle, Graeme
    [J]. HIV RESEARCH & CLINICAL PRACTICE, 2021, 22 (05) : 128 - 139
  • [30] Efficacy and safety of switching from boosted protease inhibitor plus emtricitabine/tenofovir disoproxil fumarate regimens to the single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in virologically suppressed, HIV-1-infected adults through 24 weeks: EMERALD study
    Molina, J-M
    Gallant, J.
    Orkin, C.
    Negredo, E.
    Bhatti, L.
    Gathe, J.
    Van Landuyt, E.
    Lathouwers, E.
    Hufkens, V.
    Vanveggel, S.
    Opsomer, M.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2017, 20 : 28 - 28
12345